Janet Soul, MD

Dr. Janet Soul is the Director of the Fetal-Neonatal Neurology Program where she and her team provide care to fetuses, newborns, and children whose neurologic disorders begin in utero or during the newborn period. This multidisciplinary clinical program also provides specialized training for neurology, neonatology and pediatric fellows, residents, and medical students.
Dr. Soul’s clinical research is focused on improving the management and outcome of neonatal seizures and brain injury, particularly hypoxic-ischemic brain injury. She led a randomized, double-blind, controlled trial of bumetanide to treat neonatal seizures (NCT00830531), the first neonatal seizure trial to employ a standard therapy control group. She co-chaired the Seizure Workgroup of the International Neonatal Consortium (Critical Path Institute) to develop consensus recommendations for design of neonatal seizure treatment trials. She has been funded by the NIH, March of Dimes, Hood Foundation, United Cerebral …Palsy Foundation, and others, and has served on DSMBs for NIH-funded multicenter trials. Dr. Soul has held leadership roles in the major societies and committees; she serves on the Board of the Newborn Brain Society as the Chair of the QI & Research Committee and was elected to a 2-year term on the Executive Committee of the Child Neurology Society in 2021.